COTA and PHI, a subsidiary of Texas Oncology, partner to deliver precision medicine for cancer patients
For over a decade, COTA has been tackling the most complicated cancer data to produce real-world data that can power research that will improve care and expand treatment options for patients. And now, with the integration of AI into our data curation process, we have the potential to do data-assisted clinical research with more speed […]
Research from COTA and leading global cancer center demonstrate how Real-World Data can fill cancer care gaps for older patients
COTA and Memorial Sloan Kettering Cancer Center will present the findings from their research collaboration on Diffuse Large B-Cell Lymphoma (DLBCL) studies in older patients at the upcoming American Society of Hematology Annual Meeting (ASH) next month.
The power of platforms: How data companies can accelerate the use of quality RWD for clinical research
Not all data platforms are created equal, and not all data companies are employing the same techniques to produce reliable and consistent results, notes a recent white paper from the Clinical Research Data Sharing Alliance (CRDSA).
Intern Spotlight: Marketing mavens in the making prepare for a bright professional future
Internships are one of the most important tools for young people preparing to transition from academia to a full-time career. COTA has a long history of welcoming students from all different backgrounds with widely varied interests over the summer months, giving them the opportunity to work on actual projects right alongside their mentors. These hands-on […]
Breaking through the barriers to expand real-world data use across pharma
Pharma companies are engaged in a never-ending quest to get more effective, safer therapies to patients in a faster and more accessible manner. They are constantly looking for ways to innovate, whether that’s exploring new drug classes for rare diseases or creatively connecting with audiences to enhance equity across communities in need. But there are […]
RWD and GenAI: How technology’s new power couple will revolutionize life sciences
Generative AI (GenAI) is quickly proving itself to be one of the most transformative technologies of our time with its ability to synthesize data and create new content as well as (or sometimes better than) its human creators. But GenAI needs a powerful partner if it’s going to wow users with high-quality, trustworthy, bias-free results: […]
COTA and Texas Oncology Collaborate to Advance AI-Enabled Precision Medicine
New York — COTA, Inc., in collaboration with Texas Oncology’s Precision Health Informatics, LLC (PHI), announces an innovative collaboration aimed at revolutionizing precision medicine across Texas Oncology’s community cancer centers. Leveraging COTA’s AI-powered curation engine, CAILIN™, this collaboration will transform fragmented healthcare data into actionable insights. Unlocking Insights from Electronic Health Records (EHRs) Electronic health records […]
Who, what, when…and especially where: Why care settings matter for representative real-world datasets
A vast majority of cancer patients’ care starts with a visit to a primary care provider for a routine screening or consult for a worrisome symptom. They may visit a local hospital or health system for testing and initial review by a specialist – but from there, the care pathway could take several different routes. […]
COTA and Hackensack Meridian Health at ASCO 2024
Compared to information from clinical trials, real-world data (RWD) provides oncologists and cancer researchers with data on how diverse groups of patients are treated in current clinical practice. Researchers from Hackensack Meridian Health and COTA teamed up to analyze real-world treatment outcomes for people with multiple myeloma – a type of blood cancer. The findings, […]
COTA, Baptist Health South Florida, and PreciseDx Announce Collaboration on the AI-Enabled Breast Cancer Recurrence Risk Assessment, PreciseBreast™
COTA, PreciseDx and Baptist Health South Florida announced a collaboration to assess and validate the performance of the artificial intelligence (AI) -enabled PreciseBreast™ (PDxBr) test that predicts the likelihood of invasive breast cancer (IBC) recurrence.
